Sicca Syndrome (Sjogren) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sicca Syndrome (Sjogren) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Sicca Syndrome (Sjogren) - Pipeline Review, H2 2015', provides an overview of the Sicca Syndrome (Sjogren)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sicca Syndrome (Sjogren), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sicca Syndrome (Sjogren) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sicca Syndrome (Sjogren) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sicca Syndrome (Sjogren) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sicca Syndrome (Sjogren) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sicca Syndrome (Sjogren)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Sicca Syndrome (Sjogren) Overview 8
Therapeutics Development 9
Pipeline Products for Sicca Syndrome (Sjogren) - Overview 9
Pipeline Products for Sicca Syndrome (Sjogren) - Comparative Analysis 10
Sicca Syndrome (Sjogren) - Therapeutics under Development by Companies 11
Sicca Syndrome (Sjogren) - Therapeutics under Investigation by Universities/Institutes 12
Sicca Syndrome (Sjogren) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Sicca Syndrome (Sjogren) - Products under Development by Companies 16
Sicca Syndrome (Sjogren) - Products under Investigation by Universities/Institutes 17
Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development 18
Akari Therapeutics, Plc 18
Amgen Inc. 19
Ampio Pharmaceuticals, Inc. 20
Biogen, Inc. 21
Bristol-Myers Squibb Company 22
GlaxoSmithKline Plc 23
MedImmune, LLC 24
Novartis AG 25
Redx Pharma Plc 26
Toleranzia AB 27
UCB S.A. 28
Sicca Syndrome (Sjogren) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
abatacept - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABS-11 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AMG-557 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Ampion - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
belimumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BIIB-063 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CFZ-533 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Coversin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
IMSO-001 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MEDI-4920 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Recombinant Protein for Sjogren's Syndrome - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
UCB-5857 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
VAY-736 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VM-200 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Sicca Syndrome (Sjogren) - Recent Pipeline Updates 63
Sicca Syndrome (Sjogren) - Dormant Projects 76
Sicca Syndrome (Sjogren) - Discontinued Products 77
Sicca Syndrome (Sjogren) - Product Development Milestones 78
Featured News & Press Releases 78
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 78
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for Sicca Syndrome (Sjogren), H2 2015 9
Number of Products under Development for Sicca Syndrome (Sjogren) - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics, Plc, H2 2015 18
Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc., H2 2015 19
Sicca Syndrome (Sjogren) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 20
Sicca Syndrome (Sjogren) - Pipeline by Biogen, Inc., H2 2015 21
Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H2 2015 22
Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H2 2015 23
Sicca Syndrome (Sjogren) - Pipeline by MedImmune, LLC, H2 2015 24
Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H2 2015 25
Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H2 2015 26
Sicca Syndrome (Sjogren) - Pipeline by Toleranzia AB, H2 2015 27
Sicca Syndrome (Sjogren) - Pipeline by UCB S.A., H2 2015 28
Assessment by Monotherapy Products, H2 2015 29
Number of Products by Stage and Target, H2 2015 31
Number of Products by Stage and Mechanism of Action, H2 2015 33
Number of Products by Stage and Route of Administration, H2 2015 35
Number of Products by Stage and Molecule Type, H2 2015 37
Sicca Syndrome (Sjogren) Therapeutics - Recent Pipeline Updates, H2 2015 63
Sicca Syndrome (Sjogren) - Dormant Projects, H2 2015 76
Sicca Syndrome (Sjogren) - Discontinued Products, H2 2015 77